Susquehanna International Group’s Melinta Therapeutics, Inc. Common Stock MLNT Stock Holding History

Susquehanna International Group’s Portfolio MLNT Stock Details MLNT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-277,300	Closed	-$147K	–	11371
2019 Q4	$147K	Buy	277,300 +17,700	+7%	+$42.9K	﹤0.01%	8952
2019 Q3	$989K	Buy	259,600 +149,600	+136%	+$539K	﹤0.01%	5711
2019 Q2	$732K	Buy	110,000 +48,000	+77%	+$183K	﹤0.01%	6412
2019 Q1	$220K	Buy	+62,000	New	+$336K	﹤0.01%	7744
2018 Q4	–	Sell	-10,660	Closed	-$211K	–	10467
2018 Q3	$211K	Buy	10,660 +2,820	+36%	+$71.3K	﹤0.01%	8121
2018 Q2	$249K	Buy	7,840 +3,360	+75%	+$121K	﹤0.01%	8198
2018 Q1	$166K	Sell	4,480 -4,420	-50%	-$291K	﹤0.01%	8462
2017 Q4	$703K	Buy	+8,900	New	+$659K	﹤0.01%	5937

Susquehanna International Group's MLNT Position: Q3 2019 in Review

Susquehanna International Group sold out of Melinta Therapeutics, Inc. Common Stock (MLNT) in Q3 2019, closing a stake of 143,285 shares — an estimated $516K sold.

Susquehanna International Group first reported a position in MLNT in Q4 2017 and held it in 5 quarters. The position peaked at $953K in Q2 2019. 47 funds tracked by Wall St. Rank hold MLNT as of Q3 2019.

Susquehanna International Group reported no remaining Melinta Therapeutics, Inc. Common Stock position as of Q3 2019 after selling out during the quarter.
Susquehanna International Group sold 143,285 Melinta Therapeutics, Inc. Common Stock shares in Q3 2019, an estimated $516K.
Susquehanna International Group first reported a position in Melinta Therapeutics, Inc. Common Stock in Q4 2017 and held it in 5 quarters.
Susquehanna International Group's Melinta Therapeutics, Inc. Common Stock position peaked at $953K in Q2 2019.
47 funds tracked by Wall St. Rank held Melinta Therapeutics, Inc. Common Stock as of Q3 2019.

Based on Susquehanna International Group's 13F filing for Q3 2019, filed 14 Nov 2019.